Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Management is also scheduled for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.
Details
News Market Reaction – LGND
On Feb 4, the day this news came out, LGND closed 0.26% below the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Conference date
- February 25, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Conference time
- 10:00 a.m. Eastern Time
- Scheduled fireside chat start time
- Conference edition
- 36th annual
- Oppenheimer Healthcare Life Sciences Conference iteration
Historical Context
-
Introduced 2026 revenue and EPS guidance with long‑term royalty outlook.
-
Reported strong Q3 2025 results and raised 2025 guidance metrics.
-
Announced participation in three November 2025 healthcare investor conferences.
-
Set date and call details for reporting Q3 2025 financial results.
-
Planned Dec 9, 2025 Investor Day covering strategy and royalty portfolio.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.